Lanreotide PRF

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

AdenomaAcromegalyCarcinoid SyndromeHyperinsulinismIntestinal Obstruction

45 competitors in Adenoma

#DrugCompanyPhaseTrials

1

Dostinex

Pfizer

Approved

52

Orilissa

AbbVie

Approved

13

Nolvadex

AstraZeneca

Approved

—4

Duragesic

CCephalon

Approved

—5

Octreotide Lar

Novartis

Approved

16

Lifyorli (copackaged)

CCorcept Therapeutics

Phase 3

17

Lanreotide PRF

Ipsen

Approved

18

Celebrex

PPhiladelphia Eye Associates

Phase 3

19

Olumiant

Eli Lilly

Phase 2

110

Selenium

SSWOG Cancer Research Network

Phase 3

1Show 23 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acromegaly4 trials

Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly

Completed·Ipsen·Phase 3·NCT02493517·128 enrolled

Acromegaly Resistant to Conventional Dose of First Generation Somatostatin Ligands

Completed·FFondazione Policlinico Universitario Agostino Gemelli IRCCS··NCT06607666·102 enrolled

Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly

Completed·FFederico II University·Phase 4·NCT00627796·27 enrolled

Show 1 more trial

Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

Completed·Ipsen·Phase 1/2·NCT02396953·28 enrolled

Efficacy and Safety3 trials

Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae

Completed·Ipsen·Phase 3·NCT00729313·111 enrolled

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs

Completed·Ipsen·Phase 3·NCT04852679·43 enrolled

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg

Completed·Ipsen·Phase 2·NCT02651987·99 enrolled

Intestinal Obstruction2 trials

Efficacy and Safety of Lanreotide 120 Milligram (mg) as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients

Completed·UUniversity Hospital, Ghent·Phase 2·NCT01076803·40 enrolled

Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction

Completed·Ipsen·Phase 2·NCT02275338·52 enrolled

Carcinoid Syndrome1 trial

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

Terminated·Ipsen·Phase 3·NCT00092287·4 enrolled

Adenoma1 trial

Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma

Completed·Ipsen·Phase 3·NCT00690898·108 enrolled

7 more indications

Efficacy1 trial

Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects

Completed·Ipsen·Phase 4·NCT00701363·124 enrolled

Temozolomide1 trial

Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET

Completed·Ipsen·Phase 2·NCT02231762·57 enrolled

Hyperinsulinism1 trial

Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy

Completed·SSheba Medical Center·Phase 4·NCT01070758·3 enrolled

Carcinoma1 trial

Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma

Completed·UUniversity Hospital, Ghent·Phase 3·NCT01372007·24 enrolled

Neuroendocrine Tumors1 trial

Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.

Completed·Ipsen·Phase 2·NCT02698410·40 enrolled

Tumour1 trial

Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients

Completed·Ipsen·Phase 4·NCT02075606·50 enrolled

GEP-NET1 trial

Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs

Completed·—··NCT04696042·71 enrolled

Details

Drug Info

Related News